Ad
related to: drug companies
Search results
Biohaven Crashes After Protein-Degrading Drug Misses Expectations
Investor's Business Daily· 5 hours agoThe company tested four doses of its drug, BHV-1300, which is meant to break down immunoglobulin G,...
Exclusive | Merck Nears $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 19 hours agoSuch an acquisition would steer a company known for its cancer immunotherapy, Keytruda, into the...
Highmark Members Save Significant Money on Outpatient Cancer Drug Available through CivicaScript
PRWeb· 8 hours ago"In 2020, Highmark teamed with the Blue Cross Blue Shield Association and other leading Blues health plans from across the U.S. to found CivicaScript, a nonprofit generic drug
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
CNBC· 8 hours agoIt agreed to pay $1.3 billion in cash and another $1.7 billion in future milestone-based payments...
Insmed shares skyrocket on positive trial results for lung drug By Proactive Investors
Investing.com· 1 day agoThe company said patients in the study with non-cystic fibrosis bronchiectasis who were dosed with...
Data breach at medical giant Cencora exposes info from multiple drug companies
TechRadar via Yahoo News· 2 days agoHealthcare. Almost a dozen pharmaceutical companies, including several major players, have lost...
AXIM Biotechnologies Receives Medical Device Manufacturing License
NewMediaWire via Yahoo Finance· 7 hours agoState of California Department of Public Heath Food and Drug Branch Issues the Company a License for...
From the Greeks to GLP-1s: The Complete History of Weight Loss Drugs
MediaFeed via AOL· 8 hours agoHumans have spent thousands of years experimenting with weight loss aids. While Ozempic and Wegovy...
J&J antidepressant eases symptoms, improves sleep in key trial
BioPharma Dive via Yahoo Finance· 8 hours agoJ&J is studying the drug, called seltorexant, as an “adjunctive” therapy to background treatment...
Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024
Pharmaceutical Technology via Yahoo Finance· 7 hours agoEnsifentrine is a first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor administered as a...